Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 159 entries
Sorted by: Best Match Show Resources per page
Improving measles vaccine uptake rates in Nigeria: An RCT evaluating the impact of incentive sizes and reminder calls on vaccine uptake.

PloS one

Brownstone S, Connor A, Stein D.
PMID: 32555681
PLoS One. 2020 Jun 18;15(6):e0233149. doi: 10.1371/journal.pone.0233149. eCollection 2020.

OBJECTIVE: To assess the impact of increasing incentive size and reminder calls on the measles vaccine uptake rate.DESIGN: Randomized controlled trial, randomized at individual level, stratified by clinic.SETTING: Nigeria.PARTICIPANTS: 1088 caregivers with children aged nine months or older; had...

Cite
Brownstone S, Connor A, Stein D. Improving measles vaccine uptake rates in Nigeria: An RCT evaluating the impact of incentive sizes and reminder calls on vaccine uptake. PLoS One. 2020;15(6):e0233149doi: 10.1371/journal.pone.0233149.
Brownstone, S., Connor, A., & Stein, D. (2020). Improving measles vaccine uptake rates in Nigeria: An RCT evaluating the impact of incentive sizes and reminder calls on vaccine uptake. PloS one, 15(6), e0233149. https://doi.org/10.1371/journal.pone.0233149
Brownstone, Steven, et al. "Improving measles vaccine uptake rates in Nigeria: An RCT evaluating the impact of incentive sizes and reminder calls on vaccine uptake." PloS one vol. 15,6 (2020): e0233149. doi: https://doi.org/10.1371/journal.pone.0233149
Brownstone S, Connor A, Stein D. Improving measles vaccine uptake rates in Nigeria: An RCT evaluating the impact of incentive sizes and reminder calls on vaccine uptake. PLoS One. 2020 Jun 18;15(6):e0233149. doi: 10.1371/journal.pone.0233149. eCollection 2020. PMID: 32555681; PMCID: PMC7302483.
Copy Download .nbib Format: NLM
Risk of Absence of Measles Antibody in Healthcare Personnel and Efficacy of Booster Vaccination.

Vaccines

Kim CJ, Bae JY, Jun KI, Chung HS, Kim A, Kim J, Son HJ, Lee M, Choi HJ.
PMID: 34066145
Vaccines (Basel). 2021 May 12;9(5). doi: 10.3390/vaccines9050501.

We aimed to identify the presence of the measles IgG antibody (mIgG-Ab) in healthcare personnel and finding out who needs the measles vaccination. The history of measles vaccination was obtained from the national vaccine registry. A baseline mIgG-Ab test...

Cite
Kim CJ, Bae JY, Jun KI, et al. Risk of Absence of Measles Antibody in Healthcare Personnel and Efficacy of Booster Vaccination. Vaccines (Basel). 2021;9(5)doi: 10.3390/vaccines9050501.
Kim, C. J., Bae, J. Y., Jun, K. I., Chung, H. S., Kim, A., Kim, J., Son, H. J., Lee, M., & Choi, H. J. (2021). Risk of Absence of Measles Antibody in Healthcare Personnel and Efficacy of Booster Vaccination. Vaccines, 9(5), . https://doi.org/10.3390/vaccines9050501
Kim, Chung-Jong, et al. "Risk of Absence of Measles Antibody in Healthcare Personnel and Efficacy of Booster Vaccination." Vaccines vol. 9,5 (2021). doi: https://doi.org/10.3390/vaccines9050501
Kim CJ, Bae JY, Jun KI, Chung HS, Kim A, Kim J, Son HJ, Lee M, Choi HJ. Risk of Absence of Measles Antibody in Healthcare Personnel and Efficacy of Booster Vaccination. Vaccines (Basel). 2021 May 12;9(5). doi: 10.3390/vaccines9050501. PMID: 34066145; PMCID: PMC8151488.
Copy Download .nbib Format: NLM
Internal displacement; an impediment to the successful implementation of planned measles supplemental activities in Nigeria, a case study of Benue State.

Vaccine

Korave J, Bawa S, Ageda B, Ucho A, Bem-Bura DM, Onimisi A, Dieng B, Nsubuga P, Oteri J, Fiona B, Shuaib F.
PMID: 33461836
Vaccine. 2021 Nov 17;39:C76-C81. doi: 10.1016/j.vaccine.2020.12.064. Epub 2021 Jan 16.

BACKGROUND: Measles is a highly infectious disease with great burden and implication on a displaced population with low immunity status. The disease can cause up to 140,000 deaths annually. Internal displacement during supplemental immunization activities often affects optimal reach...

Cite
Korave J, Bawa S, Ageda B, et al. Internal displacement; an impediment to the successful implementation of planned measles supplemental activities in Nigeria, a case study of Benue State. Vaccine. 2021;39:C76-C81doi: 10.1016/j.vaccine.2020.12.064.
Korave, J., Bawa, S., Ageda, B., Ucho, A., Bem-Bura, D. M., Onimisi, A., Dieng, B., Nsubuga, P., Oteri, J., Fiona, B., & Shuaib, F. (2021). Internal displacement; an impediment to the successful implementation of planned measles supplemental activities in Nigeria, a case study of Benue State. Vaccine, 39C76-C81. https://doi.org/10.1016/j.vaccine.2020.12.064
Korave, Joseph, et al. "Internal displacement; an impediment to the successful implementation of planned measles supplemental activities in Nigeria, a case study of Benue State." Vaccine vol. 39 (2021): C76-C81. doi: https://doi.org/10.1016/j.vaccine.2020.12.064
Korave J, Bawa S, Ageda B, Ucho A, Bem-Bura DM, Onimisi A, Dieng B, Nsubuga P, Oteri J, Fiona B, Shuaib F. Internal displacement; an impediment to the successful implementation of planned measles supplemental activities in Nigeria, a case study of Benue State. Vaccine. 2021 Nov 17;39:C76-C81. doi: 10.1016/j.vaccine.2020.12.064. Epub 2021 Jan 16. PMID: 33461836.
Copy Download .nbib Format: NLM
When measles came to class: a look back at the 1989 Kent State University measles epidemic.

Microbes and infection

Smith TC.
PMID: 34536576
Microbes Infect. 2021 Sep 15;104885. doi: 10.1016/j.micinf.2021.104885. Epub 2021 Sep 15.

BACKGROUND: Measles was eliminated from the United States in 2000, following a change from a single dose of measles vaccine to two doses after an epidemic 1989-1991. Several college campuses experienced outbreaks, including Kent State University (KSU) in Ohio.METHODS:...

Cite
Smith TC. When measles came to class: a look back at the 1989 Kent State University measles epidemic. Microbes Infect. 2021;104885doi: 10.1016/j.micinf.2021.104885.
Smith, T. C. (2021). When measles came to class: a look back at the 1989 Kent State University measles epidemic. Microbes and infection, 104885. https://doi.org/10.1016/j.micinf.2021.104885
Smith, Tara C. "When measles came to class: a look back at the 1989 Kent State University measles epidemic." Microbes and infection vol. (2021): 104885. doi: https://doi.org/10.1016/j.micinf.2021.104885
Smith TC. When measles came to class: a look back at the 1989 Kent State University measles epidemic. Microbes Infect. 2021 Sep 15;104885. doi: 10.1016/j.micinf.2021.104885. Epub 2021 Sep 15. PMID: 34536576.
Copy Download .nbib Format: NLM
Rubella Eradication: Not Yet Accomplished, but Entirely Feasible.

The Journal of infectious diseases

Plotkin SA.
PMID: 34590132
J Infect Dis. 2021 Sep 30;224:S360-S366. doi: 10.1093/infdis/jiaa530.

Rubella virus is the most teratogenic virus known to science and is capable of causing large epidemics. The RA 27/3 rubella vaccine, usually combined with measles vaccine, has eliminated rubella and congenital rubella syndrome from much of the world,...

Cite
Plotkin SA. Rubella Eradication: Not Yet Accomplished, but Entirely Feasible. J Infect Dis. 2021;224:S360-S366doi: 10.1093/infdis/jiaa530.
Plotkin, S. A. (2021). Rubella Eradication: Not Yet Accomplished, but Entirely Feasible. The Journal of infectious diseases, 224S360-S366. https://doi.org/10.1093/infdis/jiaa530
Plotkin, Stanley A. "Rubella Eradication: Not Yet Accomplished, but Entirely Feasible." The Journal of infectious diseases vol. 224 (2021): S360-S366. doi: https://doi.org/10.1093/infdis/jiaa530
Plotkin SA. Rubella Eradication: Not Yet Accomplished, but Entirely Feasible. J Infect Dis. 2021 Sep 30;224:S360-S366. doi: 10.1093/infdis/jiaa530. PMID: 34590132; PMCID: PMC8482023.
Copy Download .nbib Format: NLM
Vaccination and Immunity toward Measles: A Serosurvey in Future Healthcare Workers.

Vaccines

Trevisan A, Mason P, Nicolli A, Maso S, Scarpa B, Moretto A, Scapellato ML.
PMID: 33924547
Vaccines (Basel). 2021 Apr 13;9(4). doi: 10.3390/vaccines9040377.

Measles is a very contagious infectious disease, and vaccination is the only medical aid to counter the spread of the infection. The aim of this study was to evaluate the influence of vaccination schedule and type of vaccine, number...

Cite
Trevisan A, Mason P, Nicolli A, et al. Vaccination and Immunity toward Measles: A Serosurvey in Future Healthcare Workers. Vaccines (Basel). 2021;9(4)doi: 10.3390/vaccines9040377.
Trevisan, A., Mason, P., Nicolli, A., Maso, S., Scarpa, B., Moretto, A., & Scapellato, M. L. (2021). Vaccination and Immunity toward Measles: A Serosurvey in Future Healthcare Workers. Vaccines, 9(4), . https://doi.org/10.3390/vaccines9040377
Trevisan, Andrea, et al. "Vaccination and Immunity toward Measles: A Serosurvey in Future Healthcare Workers." Vaccines vol. 9,4 (2021). doi: https://doi.org/10.3390/vaccines9040377
Trevisan A, Mason P, Nicolli A, Maso S, Scarpa B, Moretto A, Scapellato ML. Vaccination and Immunity toward Measles: A Serosurvey in Future Healthcare Workers. Vaccines (Basel). 2021 Apr 13;9(4). doi: 10.3390/vaccines9040377. PMID: 33924547; PMCID: PMC8069293.
Copy Download .nbib Format: NLM
Measles Outbreak in a Roma Community in the Eastern Region of Slovakia, May to October 2018.

Zdravstveno varstvo

Hudečková H, Stašková J, Mikas J, Mečochová A, Staroňová E, Polčičová A, Baška T, Novák M, Malinovská N, Zibolenová J, Švihrová V, Nováková E, Štefkovičová M.
PMID: 33133278
Zdr Varst. 2020 Oct 18;59(4):219-226. doi: 10.2478/sjph-2020-0028. eCollection 2020 Dec.

BACKGROUND: Despite the effective National Immunization Programme of Slovakia, some population groups are incompletely vaccinated or unvaccinated. We aimed to describe the measles outbreak spread in Eastern Slovakia between May and October 2018, affecting the Roma communities in relation...

Cite
Hudečková H, Stašková J, Mikas J, et al. Measles Outbreak in a Roma Community in the Eastern Region of Slovakia, May to October 2018. Zdr Varst. 2020;59(4):219-226doi: 10.2478/sjph-2020-0028.
Hudečková, H., Stašková, J., Mikas, J., Mečochová, A., Staroňová, E., Polčičová, A., Baška, T., Novák, M., Malinovská, N., Zibolenová, J., Švihrová, V., Nováková, E., & Štefkovičová, M. (2020). Measles Outbreak in a Roma Community in the Eastern Region of Slovakia, May to October 2018. Zdravstveno varstvo, 59(4), 219-226. https://doi.org/10.2478/sjph-2020-0028
Hudečková, Henrieta, et al. "Measles Outbreak in a Roma Community in the Eastern Region of Slovakia, May to October 2018." Zdravstveno varstvo vol. 59,4 (2020): 219-226. doi: https://doi.org/10.2478/sjph-2020-0028
Hudečková H, Stašková J, Mikas J, Mečochová A, Staroňová E, Polčičová A, Baška T, Novák M, Malinovská N, Zibolenová J, Švihrová V, Nováková E, Štefkovičová M. Measles Outbreak in a Roma Community in the Eastern Region of Slovakia, May to October 2018. Zdr Varst. 2020 Oct 18;59(4):219-226. doi: 10.2478/sjph-2020-0028. eCollection 2020 Dec. PMID: 33133278; PMCID: PMC7583425.
Copy Download .nbib Format: NLM
Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma.

Molecular therapy oncolytics

Ruf B, Berchtold S, Venturelli S, Burkard M, Smirnow I, Prenzel T, Henning SW, Lauer UM.
PMID: 27119111
Mol Ther Oncolytics. 2015 Oct 07;2:15019. doi: 10.1038/mto.2015.19. eCollection 2015.

Epigenetic therapies such as histone deacetylase inhibitors (HDACi) not only have the capability to decrease tumor cell proliferation and to induce tumor cell death but also to silence antiviral response genes. Here, we investigated whether the combination of an...

Cite
Ruf B, Berchtold S, Venturelli S, et al. Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma. Mol Ther Oncolytics. 2015;2:15019doi: 10.1038/mto.2015.19.
Ruf, B., Berchtold, S., Venturelli, S., Burkard, M., Smirnow, I., Prenzel, T., Henning, S. W., & Lauer, U. M. (2015). Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma. Molecular therapy oncolytics, 215019. https://doi.org/10.1038/mto.2015.19
Ruf, Benjamin, et al. "Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma." Molecular therapy oncolytics vol. 2 (2015): 15019. doi: https://doi.org/10.1038/mto.2015.19
Ruf B, Berchtold S, Venturelli S, Burkard M, Smirnow I, Prenzel T, Henning SW, Lauer UM. Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma. Mol Ther Oncolytics. 2015 Oct 07;2:15019. doi: 10.1038/mto.2015.19. eCollection 2015. PMID: 27119111; PMCID: PMC4782956.
Copy Download .nbib Format: NLM
Cost-Effectiveness of Interventions to Improve Maternal, Newborn and Child Health Outcomes: A WHO-CHOICE Analysis for Eastern Sub-Saharan Africa and South-East Asia.

International journal of health policy and management

Stenberg K, Watts R, Bertram MY, Engesveen K, Maliqi B, Say L, Hutubessy R.
PMID: 33904699
Int J Health Policy Manag. 2021 Mar 17; doi: 10.34172/ijhpm.2021.07. Epub 2021 Mar 17.

BACKGROUND: Information on cost-effectiveness allows policy-makers to evaluate if they are using currently available resources effectively and efficiently. Our objective is to examine the cost-effectiveness of health interventions to improve maternal, newborn and child health (MNCH) outcomes, to provide...

Cite
Stenberg K, Watts R, Bertram MY, et al. Cost-Effectiveness of Interventions to Improve Maternal, Newborn and Child Health Outcomes: A WHO-CHOICE Analysis for Eastern Sub-Saharan Africa and South-East Asia. Int J Health Policy Manag. 2021;doi: 10.34172/ijhpm.2021.07.
Stenberg, K., Watts, R., Bertram, M. Y., Engesveen, K., Maliqi, B., Say, L., & Hutubessy, R. (2021). Cost-Effectiveness of Interventions to Improve Maternal, Newborn and Child Health Outcomes: A WHO-CHOICE Analysis for Eastern Sub-Saharan Africa and South-East Asia. International journal of health policy and management, . https://doi.org/10.34172/ijhpm.2021.07
Stenberg, Karin, et al. "Cost-Effectiveness of Interventions to Improve Maternal, Newborn and Child Health Outcomes: A WHO-CHOICE Analysis for Eastern Sub-Saharan Africa and South-East Asia." International journal of health policy and management vol. (2021). doi: https://doi.org/10.34172/ijhpm.2021.07
Stenberg K, Watts R, Bertram MY, Engesveen K, Maliqi B, Say L, Hutubessy R. Cost-Effectiveness of Interventions to Improve Maternal, Newborn and Child Health Outcomes: A WHO-CHOICE Analysis for Eastern Sub-Saharan Africa and South-East Asia. Int J Health Policy Manag. 2021 Mar 17; doi: 10.34172/ijhpm.2021.07. Epub 2021 Mar 17. PMID: 33904699.
Copy Download .nbib Format: NLM
Chemovirotherapy for pancreatic cancer: Gemcitabine plus oncolytic measles vaccine virus.

Oncology letters

May V, Berchtold S, Berger A, Venturelli S, Burkard M, Leischner C, Malek NP, Lauer UM.
PMID: 31612061
Oncol Lett. 2019 Nov;18(5):5534-5542. doi: 10.3892/ol.2019.10901. Epub 2019 Sep 20.

Oncolytic virotherapy with vaccine viruses employs replicative vectors, which quite selectively infect tumor cells leading to massive virus replication followed by subsequent profound tumor cell death (oncolysis). Measles vaccine virus (MeV) has already shown great oncolytic activity against different...

Cite
May V, Berchtold S, Berger A, et al. Chemovirotherapy for pancreatic cancer: Gemcitabine plus oncolytic measles vaccine virus. Oncol Lett. 2019;18(5):5534-5542doi: 10.3892/ol.2019.10901.
May, V., Berchtold, S., Berger, A., Venturelli, S., Burkard, M., Leischner, C., Malek, N. P., & Lauer, U. M. (2019). Chemovirotherapy for pancreatic cancer: Gemcitabine plus oncolytic measles vaccine virus. Oncology letters, 18(5), 5534-5542. https://doi.org/10.3892/ol.2019.10901
May, Verena, et al. "Chemovirotherapy for pancreatic cancer: Gemcitabine plus oncolytic measles vaccine virus." Oncology letters vol. 18,5 (2019): 5534-5542. doi: https://doi.org/10.3892/ol.2019.10901
May V, Berchtold S, Berger A, Venturelli S, Burkard M, Leischner C, Malek NP, Lauer UM. Chemovirotherapy for pancreatic cancer: Gemcitabine plus oncolytic measles vaccine virus. Oncol Lett. 2019 Nov;18(5):5534-5542. doi: 10.3892/ol.2019.10901. Epub 2019 Sep 20. PMID: 31612061; PMCID: PMC6781561.
Copy Download .nbib Format: NLM
Evaluation of knowledge of the United Arab Emirates population on measles and its control, following a nationwide campaign.

Avicenna journal of medicine

Ismayl G, Barqawi HJ, Harous A, Balchi M, AbuZahra D, AlMazrouei G, Elzini T.
PMID: 32110548
Avicenna J Med. 2020 Jan 23;10(1):35-40. doi: 10.4103/ajm.ajm_56_19. eCollection 2020.

INTRODUCTION: In 2015, a nationwide campaign to eradicate measles was launched by the health authorities in the United Arab Emirates (UAE). This study aimed to assess the UAE society's knowledge of measles and its control following this campaign.METHODS: A...

Cite
Ismayl G, Barqawi HJ, Harous A, et al. Evaluation of knowledge of the United Arab Emirates population on measles and its control, following a nationwide campaign. Avicenna J Med. 2020;10(1):35-40doi: 10.4103/ajm.ajm_56_19.
Ismayl, G., Barqawi, H. J., Harous, A., Balchi, M., AbuZahra, D., AlMazrouei, G., & Elzini, T. (2020). Evaluation of knowledge of the United Arab Emirates population on measles and its control, following a nationwide campaign. Avicenna journal of medicine, 10(1), 35-40. https://doi.org/10.4103/ajm.ajm_56_19
Ismayl, Ghiath, et al. "Evaluation of knowledge of the United Arab Emirates population on measles and its control, following a nationwide campaign." Avicenna journal of medicine vol. 10,1 (2020): 35-40. doi: https://doi.org/10.4103/ajm.ajm_56_19
Ismayl G, Barqawi HJ, Harous A, Balchi M, AbuZahra D, AlMazrouei G, Elzini T. Evaluation of knowledge of the United Arab Emirates population on measles and its control, following a nationwide campaign. Avicenna J Med. 2020 Jan 23;10(1):35-40. doi: 10.4103/ajm.ajm_56_19. eCollection 2020. PMID: 32110548; PMCID: PMC7014998.
Copy Download .nbib Format: NLM
[Immunity and antiviral vaccinations. Example: the respiratory mucosa].

Antibiotiques (Paris, France : 1999)

Denis F, Hantz S, Alain S.
PMID: 32288532
Antibiotiques (Paris). 2007 May;9(2):130-138. doi: 10.1016/S1294-5501(07)88778-4. Epub 2008 Jan 03.

OBJECTIVE: As the mucosal surfaces of the respiratory tract represent a major portal of entry for most human viruses and many bacteria, they seem to be a critical component of the mammalian immunologic repertoire. Thus, vaccines stimulating this local...

Cite
Denis F, Hantz S, Alain S. Immunité et vaccinations antivirales : exemple de la muqueuse respiratoire. [Immunity and antiviral vaccinations. Example: the respiratory mucosa]. Antibiotiques (Paris). 2008;9(2):130-138doi: 10.1016/S1294-5501(07)88778-4.
Denis, F., Hantz, S., & Alain, S. (2007). Immunité et vaccinations antivirales : exemple de la muqueuse respiratoire. [Immunity and antiviral vaccinations. Example: the respiratory mucosa]. Antibiotiques (Paris, France : 1999), 9(2), 130-138. https://doi.org/10.1016/S1294-5501(07)88778-4
Denis, F, et al. "Immunité et vaccinations antivirales : exemple de la muqueuse respiratoire." [Immunity and antiviral vaccinations. Example: the respiratory mucosa]. Antibiotiques (Paris, France : 1999) vol. 9,2 (2007): 130-138. doi: https://doi.org/10.1016/S1294-5501(07)88778-4
Denis F, Hantz S, Alain S. Immunité et vaccinations antivirales : exemple de la muqueuse respiratoire. [Immunity and antiviral vaccinations. Example: the respiratory mucosa]. Antibiotiques (Paris). 2007 May;9(2):130-138. doi: 10.1016/S1294-5501(07)88778-4. Epub 2008 Jan 03. French. PMID: 32288532; PMCID: PMC7146774.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 159 entries